Keyphrases
Moderate-to-severe Psoriasis
100%
Psoriasis
73%
Nationwide Registry
53%
Risk Factors
53%
Staphylococcus Aureus Colonization
46%
Human alphaherpesvirus
46%
Atopic Dermatitis
46%
Biological Therapy
46%
Systemic Therapy
46%
Prospective Birth Cohort
46%
Cheek
46%
Childhood Asthma
46%
Psoriasis Severity
46%
Inflammatory Bowel Disease
46%
Diagnostic Model
46%
Type I Diabetes
46%
Type 1 Diabetes Mellitus (T1DM)
46%
Bootstrap
46%
Risk Consequence
46%
Diagnostic Prediction Model
46%
Incidence Risk
46%
Biological Agents
46%
Methotrexate
46%
Development Validation
46%
Internal Validation
46%
C-statistic
30%
National Registry
30%
Tumour Necrosis Factor Inhibitor (TNFi)
30%
IL-17 Inhibitors
30%
Alphaherpesvirus
30%
S. Aureus Colonization
25%
Systemic Treatment
17%
Denmark
17%
Hazard Ratio
15%
Boosting Learning
15%
Gradient Boosting
15%
Administrative Health Records
15%
Bootstrap Correction
15%
T Helper 1
15%
Machine Learning Techniques
15%
Hospital Contacts
15%
Administrative Register Data
15%
Asthma
15%
30-day Mortality
15%
Disease Severity
15%
Underfitting
15%
Gradient Boosting Machine
15%
Epidemiology
15%
Register Data
15%
Discrimination Power
15%
Pharmacology, Toxicology and Pharmaceutical Science
Psoriasis
92%
Biological Product
50%
Staphylococcus Aureus
46%
Insulin Dependent Diabetes Mellitus
46%
Atopic Dermatitis
46%
Inflammatory Bowel Disease
46%
Asthma
46%
Infection
46%
Methotrexate
46%
Tumor Necrosis Factor Inhibitor
26%
Interleukin 17
26%
Prevalence
18%
Systemic Treatment
13%
Interleukin 12
13%
Cohort Study
11%
Autoimmune Disease
6%
Comorbidity
6%
Immunopathology
6%
Disease
6%
Famciclovir
6%
Corticosteroid
6%
Immunosuppressive Agent
6%
Valaciclovir
6%
Aciclovir
6%
Immunology and Microbiology
Biological Product
61%
Prevalence
50%
Asthma
46%
Inflammatory Bowel Disease
46%
Staphylococcus Aureus
46%
Cheek
46%
Methotrexate
46%
Atopic Dermatitis
46%
Interleukin 17
30%
TNF Inhibitor
30%
T Helper Cell
26%
Interleukin 12
15%
Immunosuppressive Drug
7%
Immunopathology
6%
Comorbidity
6%
Autoimmune Disease
6%
